Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Corrective Actions Lead Beijing FDA To Lift Drug Ad Suspensions, But SFDA Uncovers More Infractions

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Food and Drug Administration Nov. 7 issued a report summarizing illegal pharmaceutical and medical device advertisements uncovered by China's local FDAs, and announced that advertising licenses for nine drugs and seven medical devices would be suspended for one year because of incorrect or exaggerated content

You may also be interested in...

China’s Top TCM Authority Institutes National Advertisement Inquiry System To Stop Misleading Ads

SHANGHAI - China's State Administration of Traditional Chinese Medicine instituted the country's first national TCM medical advertisement inquiry system on Aug. 1 in an attempt to check frivolous advertising of TCM services

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts